Stay updated with breaking news from Device Designations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the pivotal U.S.
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood
Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data analysis completion expected before year-end.PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorptio
PRINCETON, N.J., Oct. 05, 2023 -- CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification,...